-+ 0.00%
-+ 0.00%
-+ 0.00%

NEW DRUG APPLICATION SUBMISSION INITIATED FOR ZIPALERTINIB PLUS CHEMOTHERAPY IN FIRST-LINE EGFR EXON 20 INSERTION MUTATION NSCLC FOR REVIEW UNDER FDA REAL-TIME ONCOLOGY REVIEW PROGRAM

路透·10/01/2026 23:30:00

請登錄查看新聞詳情